RE:RE:RE:RE:More volume/higher valuation? This is how to get there.TH has dug themselves a very deep hole on the capital markets side of the equation. Our CEO has said he has a plan to fix that and I am sure he does. My best guess is they will be unveiling that plan once they have some news to make noise about. Most likely, that news will be the NASH protocol harmonization (hopefully) and finalization. But maybe it will involve something on cancer too. I hope the NASH protocol is not too far off because the stock is dying on the vine without news and I suspect there won't be a lot of news until we get the NASH protocol finalized. At that point, the LSA relationship will likely kick in. We will get the announcement of the fianlised protocol, we will get a LSA report with a big price target on it and a more fully fleshed out NASH model and some indication of where the company might go on cancer. We will likely get a R&D Day to talk about that and/or a KOL sessions for both cancer and NASH. I really do not have a good idea of how effective LSA is but they sure have a hefty staff of highly qualified analysts (Phd's) and I cannot imagine they could afford that if they were not having some success for their clients.
So, this complete lack of interest in TH will likely soon be over. The sooner the better, however. And hopefully, the LSA influence will help drive much better decisions on the company's interaction with the marketplace in the future and allow that hole they diu for themselves to be transformed into a mountain of better, more consistent news flow. The rebranded TH should be one where the leadership team gets credit for their vision on cancer and NASH rather than their mistakes on share offerings, lack of guidance and nearly absent engagement from institutional analysts and investors.
scarlet1967 wrote: Last January they came out with the good PR instead of letting market digest it and attending conferences to create excitement about their progress two days later they sold one third of the company at a cheap price with warrants attached to it, the investor presentation was down for 8 days during the crucial period when all these new investors could gather some information about what they bought into, no mitigation attempts to at least convince some to stay put so they effectively sent a message this is what we think the company is worth going forward we are high risk high return company feel free to sell your shares.
Another message was they were not confident about the company's future prospect so they hit the sell button as fast as the good news were announced. Wouldn't it be better after the long wait for NASH when they eventually shed some light on it to go out there and sell the story?
scarlet1967 wrote: Often specifically R&D companies do dilution as they need to fund their programs in absence of revenues and each time it will put a lid on the valuation as those new shareholders have been offered shares below market value so many choose to sell for a small profit, THTX did it in the last decade three times at $3 then at $5 and the recent one. I remember each time it took months for the stock to get moving because of the same reason. My point about this company wasn't about offerings but proactive marketing. This company has one drug one completed phase 1 NASH trial yet they have average daily volume at millions versus THTX's few thousand, they have 30 k followers on Stocktwits versus THTX's 900.
Their CEO goes out there promoting their business actively to get even more attention of mostly retail investors to their company on a well followed retail platform. This is the part THTX is not doing and should be doing so get pass the sticky point of low volume. As it is now the low volume make it almost impossible to invest or trade the stock. They need more followers and their strategies so far hasn't changed anything.
qwerty22 wrote: So what role did stock offerings play in this comany? Just for balance.
My maths might be wrong.
Before Nov 2020 they had 10 mil shares
They then sold 23 mil shares at 1.50
In Feb 2021 they sold 44mil shares at 2.00
The SP is now 1.63
I expect the original shareholder were mostly insider etc, knew what they were doing, maybe even participated in the offerings which are clearly about building in effect a new company (what previously existed came from a merger of 3 companies in 2016, somebody with more knowledge can explain this)
If this is part of the Hepion story alongside YouTube channels then you'd be advocating for our complete wipeout as legacy shareholders. I'm not sure what the relevance to THTX is. Are the guys that bought at $2 (it's now 1.63) meant to be the winners? I see the guys that bought in Nov are in the green still. You looking for 6x dilution of original shareholders? And that high vol, which came it seems from the last offering rather than YouTube channels looks to be rapidly declining and has been associated with a declining share price. If you transposed Hepion's experience onto THTX, where would be the happy story for us?
scarlet1967 wrote:
This company just finished their only phase 1 NASH trial entering phase 2a, nothing more in their pipe line, no commercialized drugs, market cap US 124 M, average daily volume 3.7 M, they have nearly 29k follower on the Stocktwitts yet their CEO goes on seeking alpha CEO interview YouTube platform with 9.5k subscriber, those interviews get published on seeking alpha website and mobile app.
“Hepion Pharmaceuticals (NASDAQ: HEPA) is a biopharmaceutical company focused on developing drug therapy treatment for chronic liver diseases in the US. It's currently developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. Today we talk to Hepion CEO Dr. Robert Foster, who has over 30 years of pharma and biotech experience, about the trials, differences between nonalcoholic steatohepatitis (NASH) - liver inflammation and damage caused by a buildup of fat in the liver - and nonalcoholic fatty liver disease (NAFLD), and the decision to focus on cyclophilins.”
https://youtu.be/K-8I_O-KU74